Diamyd Medical selects Cytiva’s FlexFactory platform to make precision medicine type-1 diabetes vaccine
- FlexFactory platform enables Diamyd Medical to manufacture its key protein GAD65 for type 1 diabetes precision-medicine vaccine
- Diamyd’s biologics manufacturing is located in Umeå, Sweden
- FlexFactory is a configurable single-use bioprocess manufacturing platform
March 16, 2021
Diamyd Medical will install a new Cytiva FlexFactory platform in Umeå, Sweden. Once up and running, the clinical-stage biopharmaceutical company will begin manufacturing its precision-medicine vaccine. The first of its kind, the type 1 diabetes vaccine works to reprogram immune cells to prevent the destruction of pancreatic insulin-producing B-cells.
Globally, more than 1.1 million children and adolescents live with the autoimmune disease, type 1 diabetes1. Diamyd Medical develops therapies that target the underlying causes of diabetes. During clinical development of the vaccine, the global pandemic threatened its progress.
Ulf Hannelius, President & CEO, Diamyd Medical, says: “The importance of being in control of your own manufacturing process for biologics has never been so apparent as during the present pandemic. With FlexFactory we will be able to produce the biologic GAD, the active product ingredient in our diabetes vaccine. We chose Cytiva’s solutions thanks to the flexibility. The platform we use today can be transformed tomorrow to meet future growth and demand.”
Olivier Loeillot, Vice President of BioProcess, Cytiva, says: “We developed our FlexFactory platform to be flexible and scalable so companies like Diamyd can respond to changing demands. Whether it’s smaller targeted therapies or larger scale manufacturing, the goal is the same: getting life changing therapies into those most vulnerable – quicker and more efficiently.”
The vaccine, the antigen-specific immunotherapy Diamyd® targets approximately fifty percent of individuals recently diagnosed with type I diabetes, specifically individuals who carry the DR3-DQ2 human leukocyte antigen haplotype.
In over 80 locations around the world, FlexFactory integrated manufacturing lines accelerate research, clinical trials and commercial production of advanced and novel therapeutics and vaccines.
To learn more about Cytiva’s enterprise solutions click here.
To learn about Diamyd Medical’s type 1 diabetes therapies click here.
About Cytiva
Cytiva is a global life sciences leader with more than 7,000 associates across 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients.
About Diamyd Medical AB
Diamyd Medical develops therapies for type 1 diabetes; the diabetes vaccine Diamyd®, an antigen-specific immunotherapy for the preservation of endogenous insulin production, and the GABA-based investigational drug Remygen® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. Diamyd Medical is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser; phone: +46 8-528 00 399, e-mail: [email protected]
Media Contact:
Tania Kimball
[email protected]
+1 978-995-3184